Document |
Document Title |
WO/2017/165822A1 |
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...
|
WO/2017/161095A1 |
Provided herein are rigid macrocycles comprising a first redox-active subunit and a second redox-active subunit, wherein the first redox-active unit and the second redox-active unit are different subunits. Also provided herein are method...
|
WO/2017/156454A1 |
There are provided inter alia stable anti-cancer compounds and splice modulators and methods of synthesis and use thereof.
|
WO/2017/149551A1 |
The present invention relates to new generation of aurone alkaloid agents, their method of preparation and their use as drugs for treatment of tuberculosis.
|
WO/2017/144639A1 |
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
WO/2017/140728A1 |
The present invention relates to lactam derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of the bromodomain-containing protein TAF1 (i...
|
WO/2017/141202A1 |
The present invention relates to a crystalline Form A of complex of Empagliflozin with L-Proline and process for preparation thereof. The present invention further relates to a method of preparing pure crystalline Empagliflozin via forma...
|
WO/2017/137319A1 |
The present invention relates to compounds of the general formula (I), in which Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
WO/2017/137895A1 |
The subject-matter of the present invention relates to the synthesis of new dendrimeric molecules based on polyhydroxylated pyrrolidines obtained by means of Click Chemistry reactions. The proposed molecules inhibit the enzymes N-acetylg...
|
WO/2017/137339A1 |
The present invention relates to compounds of the general formula (I), where to Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
WO/2017/137338A1 |
The present invention relates to compounds of the general formula (I), wherein Q, V, T, W, X, Y and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
WO/2017/125900A1 |
The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl) chromans of formula I. The intermediates thus obtained can ...
|
WO/2017/122209A2 |
Disclosed herein are compounds capable of inhibiting dimerization of NF-κB, for example, p65-p65 homodimerization and/or p50-p65 heterodimerization, the compounds being represented by formula I: X-L2-L1-L'2-Y Formula I wherein X, Y, L1,...
|
WO/2017/121444A1 |
Compounds of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
|
WO/2017/114937A1 |
The invention relates to a compound of general formula (I), where Y, Y', Z, Z' and X, as well as the structural units D1 to D3 having coefficients o, p and q and the groups A1 and A2 are respectively defined as disclosed in claim 1. The ...
|
WO/2017/113964A1 |
Provided is a novel stilbene derivative, being a compound having the general formula (I) or general formula (II), or an acceptable salt formed from the compound having the general formula (I) or general formula (II) with an inorganic aci...
|
WO/2017/112777A1 |
Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are compositions and methods for treating cancer and inflammatory disease.
|
WO/2017/106520A1 |
Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in ...
|
WO/2017/102064A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
WO/2017/100558A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
WO/2017/095704A1 |
Polymerizable compositions comprising a redox initiator system is disclosed. The redox initiators comprises a photolabile reducing agent, that photolyzes and initiates the redox cycle. Dental compositions comprising dental resins and the...
|
WO/2017/095075A1 |
The present invention provides a novel compound capable of improving the luminous efficiency, stability and lifespan of a device, an organic electric device using the same, and an electronic device .
|
WO/2017/089389A1 |
The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used in the treatment of Human African TRypanosomiasis.
|
WO/2017/083914A1 |
The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of inf...
|
WO/2017/082556A1 |
The present invention relates to a compound represented by [chemical formula A] or [chemical formula B] and an organic light-emitting device comprising same.
|
WO/2017/079678A1 |
The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4
-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical comp...
|
WO/2017/072090A1 |
The present invention relates to the use of anti-Aβ antibodies and serum amyloid P component (SAP) depleting compounds in the treatment of diseases associated with amyloid deposition, such as Alzheimer's disease.
|
WO/2017/071791A1 |
The present invention relates to compounds comprising a heterocyclic group substituted with a fluoranthene group and a particular aromatic or heteroaromatic group. The compounds are suitable for use in electronic devices, in particular o...
|
WO/2017/065419A1 |
The present disclosure relates to organic electroluminescent compounds, and a host material, an electron buffer material, an electron transport material and an organic electroluminescent device comprising the same. By using the organic e...
|
WO/2017/066606A1 |
In one aspect, the present disclosure provides epothilone analogs of the formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein...
|
WO/2017/066705A1 |
Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infect...
|
WO/2017/055859A1 |
The invention provides a compound of formula (I): (I) or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions co...
|
WO/2017/052169A1 |
The present specification relates to a novel xanthene-based compound, a colorant composition containing the same, and a resin composition containing the same.
|
WO/2017/049871A1 |
The present invention provides a 4-substituted coumarin derivative having a structural formula as shown by formula 1, and also provides a preparation method and use of the 4-substituted coumarin derivative. Said compound has a stronger a...
|
WO/2017/050298A1 |
The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.
|
WO/2017/049081A1 |
The present invention enables three-dimensional nanofabrication by isotropic shrinking of patterned hydrogels. A hydrogel is first expanded, the rate of expansion being controlled by the concentration of the crosslinker. The hydrogel is ...
|
WO/2017/045751A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.
|
WO/2017/041228A1 |
The present invention relates to the field of pharmaceutical synthesis, in particular to a method for preparing a hexahydrofurofuranol derivative, an intermediate thereof and a preparation method thereof. The preparation method uses a co...
|
WO/2017/043636A1 |
To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urinatio...
|
WO/2017/037146A1 |
The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
|
WO/2017/031038A1 |
The invention relates to salinomycin derivatives such as compounds having the structure of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a therapeutically effective amount of compounds ...
|
WO/2017/028927A1 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, and Z- have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a me...
|
WO/2017/025868A1 |
A compound of Formula (I) is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as TD02 inhibitors. The invention also relates to the ...
|
WO/2017/025427A1 |
The present invention relates to novel strigolactam derivatives, to processes for preparing these derivatives including intermediate compounds, to plant growth regulator or seed germination promoting compositions comprising these derivat...
|
WO/2017/024980A1 |
Disclosed is a crystallization separation method for a nebivolol hydrochloride intermediate mixture, which comprises the following steps: step 1, adding an alcohol solvent or a mixed solvent of an alcohol and an alkane to a nebivolol hyd...
|
WO/2017/019589A1 |
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The p...
|
WO/2017/012970A2 |
Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and con...
|
WO/2017/014315A1 |
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...
|
WO/2017/009804A1 |
The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases a...
|
WO/2017/005567A1 |
The invention relates to N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl...
|